Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2016-000286-23 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the recommended safe dose for participants with relapsed/refractory (R/R) B cell malignancies who failed at least 1 but no more than 3 prior therapies. Part 1 of this study is no longer enrolling participants.
Arms 1 & 2 of Part 2 of this study will test different doses of TL-895 in participants with R/R CLL or SLL who have failed at least 1 prior therapy. Arms 1 & 2 of Part 2 of this study is randomized (like the flip of a coin) to receive a specific treatment dose. If someone participates in arms 1 or 2 of Part 2, the dose they receive will be either 100mg twice a day or 150mg twice a day.
Arms 3 and 4 of Part 2 of this study will test the 150mg and 100mg BID dose of TL-895, respectively in treatment naïve participants with CLL/SLL.
Arms 5 and 6 of Part 2 will test 150mg TL-895 BID in combination with 240 mg navtemadlin QD in participants with relapsed/refractory and treatment naïve without 17p(del). Arm 7 will test 150mg TL-895 in combination with 240 mg navtemadlin QD in participants with relapsed/refractory CLL/SLL with 17p(del).
Every participant in this study will receive TL-895.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TL-895 80/160 mg QD in R/R Participants | Experimental | Participants received TL-895 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by TL-895 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 300 mg QD in R/R Participants | Experimental | Participants received TL-895 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 600 mg QD in R/R Participants | Experimental | Participants received TL-895 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 300 mg BID in R/R Participants | Experimental | Participants received TL-895 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 900 mg QD in R/R Participants | Experimental |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TL-895 | Drug | TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Part 1 (Dose Escalation): DLTs (Dose Limiting Toxicities) during Cycle 1 | DLT is defined as any of the adverse event (AEs) of a certain grade or above, related to drug. | Baseline up to the end of cycle 1 (28 days) |
| Part 2 (Dose Expansion): Overall Response Rate (ORR) | The proportion of subjects achieving CR, CRi, nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PR-L) at any time while on the study based on iwCLL response criteria (2), as assessed by investigators | Baseline up to end of study (2 years after last patient enrolled) |
| Measure | Description | Time Frame |
|---|---|---|
| Part 1 (Dose Escalation): Best Overall Response (BOR)/Progression Free Survival (PFS) | Defined by the length of time during the treatment of the disease, that a participant lives with the disease but it does not get worse based on investigator assessments | Baseline up to 6 months on treatment |
| Part 2 (Dose Expansion): Overall CR/CRi rate |
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | United States | ||
| The West Clinic |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | Eugenio Gaudio, Chiara Tarantelli, Emanuele Zucca, Davide Rossi, Anastasios Stathis, Francesco Bertoni. The two novel BTK-inhibitors M2951 and M7583 show in vivo anti-tumor activity in pre-clinical models of B cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4182. doi:10.1158/1538-7445.AM2017-4182 | ||
| 37989777 | Background | Goodstal SM, Lin J, Crandall T, Crowley L, Bender AT, Pereira A, Soloviev M, Wesolowski JS, Iadevaia R, Schelhorn SE, Ross E, Morandi F, Ma J, Clark A. Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies. Sci Rep. 2023 Nov 21;13(1):20412. doi: 10.1038/s41598-023-47735-z. | |
| 33896333 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants received TL-895 900 mg PiC orally QD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
|
| TL-895 100 mg BID in R/R Participants | Experimental | Participants received TL-895 100 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 150 mg BID in R/R Participants | Experimental | Participants received TL-895 150 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 150 mg BID in Treatment Naïve Participants | Experimental | Participants received TL-895 150 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 100 mg BID in Treatment Naïve Participants | Experimental | Participants received TL-895 100 mg BID orally with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants without 17p(del) | Experimental | Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 150 mg BID & navtemadlin 240mg QD in Treatment Naïve Participants without 17p(del) | Experimental | Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| TL-895 150 mg BID & navtemadlin 240mg QD in R/R Participants with 17p(del) | Experimental | Participants received navtemadlin 240 mg administered QD on Days 1-7 in combination with TL-895 150 mg BID orally with food for 28 days with in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study. |
|
| Navtemadlin | Drug | Navtemadlin is an experimental MDM2 anticancer drug taken by mouth. |
|
The proportion of subjects achieving CR/CRi based on iwCLL response criteria |
| Baseline up to end of study (2 years after last patient enrolled) |
| Part 2: Duration of Clinical Response (DOR) | Time from initial response to disease progression or death from any cause | Baseline up to end of study (2 years after last patient enrolled) |
| Part 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) | Incidence, nature, severity of treatment-emergent adverse events (TEAEs), and deaths, including cause of death, from screening up to the end of study visit of participants with CLL/SLL who have failed at least 1 line of therapy | Baseline up to end of study (2 years after last patient enrolled) |
| Part 2: Assessment of Safety and Tolerability via Clinical Measurements | Assessments including but not limited to clinical laboratory measurements, ECGs, vital signs, and ECOG performance | Baseline up to end of study (2 years after last patient enrolled) |
| Germantown |
| Tennessee |
| 38138 |
| United States |
| Debreceni Egyetem - Borgyógyászati Klinika | Debrecen | 4002 | Hungary |
| Eger Markhot Ferenc Kórház | Eger | 3300 | Hungary |
| Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Istituto di Ematologia e Oncologia Medica | Bologna | 40138 | Italy |
| Examen sp. z o. o. | Skorzewo | Poznań | 60-185 | Poland |
| Pratia MCM Krakow | Krakow | 30-510 | Poland |
| Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli Oddzial Hematologiczny | Lublin | 20-090 | Poland |
| Szpital Wojewódzki | Opole | 46-020 | Poland |
| Nasz Lekarz Przychodnie Medyczne | Torun | 87-100 | Poland |
| Saint Petersburg State Medical University | Saint Petersburg | 197022 | Russia |
| Yaroslavl Regional Clinical Hospital | Yaroslavl | 150023 | Russia |
| Communal Non-profit Enterprise Regional Center of Oncology | Kharkiv | 61000 | Ukraine |
| Kyiv City Clinical Hospital #4 | Kyiv | 03110 | Ukraine |
| Mykolaiv Regional Clinical Hospital | Mykolaiv | 54058 | Ukraine |
| University College London Hospitals - NIHR/Wellcome Trust | London | United Kingdom |
| Derriford Hospital - Dept of Haematology | Plymouth | United Kingdom |
| Background |
| Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Dyroff M, Gribben JG, Dlugosz-Danecka M, Zinzani PL. Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. Leuk Lymphoma. 2021 Oct;62(10):2392-2399. doi: 10.1080/10428194.2021.1913139. Epub 2021 Apr 24. |
| ID | Term |
|---|---|
| D012008 | Recurrence |
| D020522 | Lymphoma, Mantle-Cell |
| D016403 | Lymphoma, Large B-Cell, Diffuse |
| D015451 | Leukemia, Lymphocytic, Chronic, B-Cell |
| D008223 | Lymphoma |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D008228 | Lymphoma, Non-Hodgkin |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D016393 | Lymphoma, B-Cell |
| D015448 | Leukemia, B-Cell |
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D006402 | Hematologic Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| C000723723 | navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid |
Not provided
Not provided
Not provided